Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

被引：0
作者：
Pedro C. Barata
Dhrmesh Gopalakrishnan
Vadim S. Koshkin
Prateek Mendiratta
Matt Karafa
Kimberly Allman
Allison Martin
Jennifer Beach
Pam Profusek
Allison Tyler
Laura Wood
Moshe Ornstein
Timothy Gilligan
Brian I. Rini
Jorge A. Garcia
Petros Grivas
机构：
[1] Taussig Cancer Institute Cleveland Clinic,Department of Hematology & Medical Oncology
[2] Cleveland Clinic,Department of Hospital Medicine
[3] Cleveland Clinic,Quantitative Health Sciences
[4] University of Washington and Fred Hutchinson Cancer Research Center,Department of Medicine, Division of Oncology
[5] Seattle Cancer Care Alliance,undefined
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 361
页数：8
相关论文
共 50 条
  • [21] Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
    Tural, Deniz
    Selcukbiricik, Fatih
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Erman, Mustafa
    Coskun, Hasan Senol
    Artac, Mehmet
    Kilickap, Saadettin
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (03) : 585 - 591
  • [22] Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma
    Nassar, Amin H.
    Lundgren, Kevin
    Kim, Jaegil
    Choueiri, Toni K.
    Sonpavde, Guru P.
    Kwiatkowski, David J.
    Bellmunt, Joaquim
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 6
  • [23] Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello, Giandomenico
    Catalano, Martina
    Nobili, Stefania
    Santi, Raffaella
    Mini, Enrico
    Nesi, Gabriella
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) : 1 - 14
  • [24] Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
    Thomas Powles
    Mark Kockx
    Alejo Rodriguez-Vida
    Ignacio Duran
    Simon J. Crabb
    Michiel S. Van Der Heijden
    Bernadett Szabados
    Albert Font Pous
    Gwenaelle Gravis
    Urbano Anido Herranz
    Andrew Protheroe
    Alain Ravaud
    Denis Maillet
    Maria Jose Mendez
    Cristina Suarez
    Mark Linch
    Aaron Prendergast
    Pieter-Jan van Dam
    Diana Stanoeva
    Sofie Daelemans
    Sanjeev Mariathasan
    Joy S. Tea
    Kelly Mousa
    Romain Banchereau
    Daniel Castellano
    Nature Medicine, 2020, 26 : 983 - 983
  • [25] Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
    Thomas Powles
    Mark Kockx
    Alejo Rodriguez-Vida
    Ignacio Duran
    Simon J. Crabb
    Michiel S. Van Der Heijden
    Bernadett Szabados
    Albert Font Pous
    Gwenaelle Gravis
    Urbano Anido Herranz
    Andrew Protheroe
    Alain Ravaud
    Denis Maillet
    Maria Jose Mendez
    Cristina Suarez
    Mark Linch
    Aaron Prendergast
    Pieter-Jan van Dam
    Diana Stanoeva
    Sofie Daelemans
    Sanjeev Mariathasan
    Joy S. Tea
    Kelly Mousa
    Romain Banchereau
    Daniel Castellano
    Nature Medicine, 2023, 29 : 3271 - 3271
  • [26] Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
    Hoffman-Censits, J.
    Rosenberg, J. E.
    van Der Heijden, M.
    Dreicer, R.
    Perez Gracia, J. L.
    Petrylak, D. P.
    Retz, M. M.
    Sabbatini, R.
    Naglieri, E.
    Caserta, C.
    Maruzzo, M.
    Iacovelli, R.
    Galli, L.
    McDermott, R.
    Morales Barrera, R.
    Bonfill, T.
    De Ducla, S.
    Ding, B.
    Linsenmeier, J.
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 372 - +
  • [27] Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies
    Hara, Takuto
    Suzuki, Kotaro
    Okada, Keisuke
    Chiba, Koji
    Teishima, Jun
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (10) : 1168 - 1170
  • [28] A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines
    Patel, Dixita M.
    Mateen, Ruba
    Qaddour, Noor
    Carrillo, Alessandra
    Verschraegen, Claire
    Yang, Yuanquan
    Li, Zihai
    Sundi, Debasish
    Mortazavi, Amir
    Collier, Katharine A.
    Tsuzuki, Toyonori
    CANCERS, 2024, 16 (02)
  • [29] Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials
    Sen, Selcuk
    Sabirli, Soner
    Ozyigit, Tolga
    Uresin, Yagiz
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2013, 4 (05) : 232 - 241
  • [30] Clinical efficacy of contemporaneous system therapy with immunotherapy in metastatic urothelial carcinoma, a monocentric evaluation
    Isgandarov, A.
    Darr, C.
    Hilser, T.
    Al-Nader
    Hadaschik, B. A.
    Grunwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 318 - 318
12345